Th22细胞及IL-22因子在原发性肝细胞肝癌发生发展中的表达及意义

doi:10.3969/j.issn.2095-9400.2019.01.004

摘要
图/表
参考文献
相关文章 (10)

全文: PDF (1418 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：研究Th22细胞及IL-22分子在原发性肝细胞肝癌发生发展中的表达及意义。方法：选取2015年1月至2016年12月于温州医科大学附属第三医院住院治疗的慢性乙肝肝硬化患者42例（肝硬化组），肝癌伴乙肝肝硬化患者38例（肝癌组），及门诊健康受检者30例（健康对照组），慢性乙型肝炎患者21例（慢性乙肝组）。收集各组谷草转氨酶（AST）、谷丙转氨酶（ALT）、总胆红素（TBIL）和白蛋白（ALB）信息，并分别收集清晨空腹肘静脉血2份，一份用ELISA方法测定IL-22表达水平，另一份用流式细胞仪测定Th22细胞含量。统计分析各组指标的差异。结果：肝硬化组和肝癌组患者的AST、ALT、TBIL和ALB显著高于慢性乙肝组和健康对照组（P＜0.01），肝癌组患者AST、ALT、TBIL和ALB高于乙肝肝硬化组（P＜0.01），慢性乙肝组和健康对照组间AST、ALT、TBIL和ALB差异无统计学意义（P＞0.05）。此外，随着肝癌的发生发展，AST、ALT、TBIL和ALB逐渐升高（P＜0.05）。肝硬化组及肝癌组的Th22细胞含量及IL-22表达水平均高于慢性乙肝组和健康对照组（P＜0.05），肝癌组的Th22细胞含量及IL-22表达水平高于肝硬化组（P＜0.05），慢性乙肝组的Th22细胞含量及IL-22表达水平与健康对照组差异无统计学意义（P＞0.05）。随着肝癌的发生发展，Th22细胞含量及IL-22表达水平逐渐升高（P＜0.05）。结论：Th22及IL-22水平可能与肝癌的发生发展具有相关性。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	施振静
	吴道义
	吴丽丽
	乔彬彬
	郑冰汝
	李成
	施昌盛
	虞希祥

关键词 ：原发性肝癌, Th22细胞, 白细胞介素-22, 肝炎, 乙型

Abstract：Objective: To study the expression and significance of Th22 cells and IL-22 in the development and progression of primary hepatocellular carcinoma. Methods: A total of 42 hospitalized patients with chronic hepatitis B cirrhosis (cirrhosis group), 38 hospitalized patients with hepatocellular carcinoma (hepatocellular carcinoma group), 30 healthy volunteers (healthy group) and 21 cases of chronic hepatitis B (CHB group) were randomly selected from the Third Affiliated Hospital of Wenzhou Medical University from January 2015 to December 2016. The differences in AST, ALT, TBIL and ALB values were analyzed. Blood was collected intravenously into 2 heparin anticoagulant tubes, one for testing IL-22 expression level and the other for determination of Th22 cell levels using flow cytometry. The statistics of Th22 and IL-22 levels were analyzed. Results: The AST, ALT, TBIL and ALB values in patients with cirrhosis and hepatocellular carcinoma were significantly higher than those in the CHB group and healthy group (P<0.01). The AST, ALT, TBIL and ALB values of patients in the hepatocellular carcinoma group were higher than those in cirrhosis group (P<0.01). There was no significant difference between CHB group and healthy group (P>0.05). In addition, the AST, ALT, TBIL and ALB gradually increased with the development of hepatocellular carcinoma (P<0.05). The levels of Th22 and IL-22 in liver cirrhosis group and hepatocellular carcinoma group were higher than those in healthy subjects (P<0.05). Th22 and IL-22 levels in hepatitis B liver cancer group were higher than those in hepatitis B cirrhosis group (P<0.05). The levels of Th22 and IL-22 were gradually increased with the development of hepatocellular carcinoma (P<0.05). Conclusion: Th22 and IL-22 may be related to the occurrence and development of HCC.

Key words： primary hepatocellular carcinoma Th22 cells interleukin-22 hepatitis B

基金资助:浙江省医药卫生科技计划项目（2015KYB369）；瑞安市科技创新专项资金（MS2015014，MS2015012，MS2015020）

通讯作者: 虞希祥，主任医师，Email：yudsa@126.com。

作者简介: 施振静（1983-），男，浙江瑞安人，主治医师。

链接本文:

https://xb.wmu.edu.cn/CN/10.3969/j.issn.2095-9400.2019.01.004 或 https://xb.wmu.edu.cn/CN/Y2019/V49/I1/15

[1] ZHAO F, KORANGY F, GRETEN T F. Cellular immune suppressor mechanisms in patients with hepatocellular carci-noma[J]. Dig Dis, 2012, 30(5): 477-482.
[2] SUHAIL M, ABDEL-HAFIZ H, ALI A, et al. Potential mechanisms of hepatitis B virus induced liver injury[J]. World J Gastroenterol, 2014, 20(35): 12462-12472.
[3] MOUGIAKAKOS D, CHOUDHURY A, LLADSER A, et al.
Regulatory T cells in cancer[J]. Adv Cancer Res, 2010, 107: 57-117.
[4] 杜勇, 黄智铭, 林秀清, 等. 肝癌小鼠模型中调节性T细胞对树突状细胞的作用[J]. 温州医科大学学报, 2017, 47(10): 718-722.
[5] WANG K, VELLA A T. Regulatory T cells and cancer: A two-sided story[J]. Immunol Invest, 2016, 45(8): 797-812.
[6] 庄磊, 魏永刚, 宋其同, 等. BCLC B期肝癌术后行索拉非尼治疗的疗效分析[J]. 温州医科大学学报, 2015, 45(12): 929-931.
[7] LI J, WANG Z, MAO K, et al. Clinical significance of serum T helper 1/T helper 2 cytokine shift in patients with non-small cell lung cancer[J]. Oncol Lett, 2014, 8(4): 1682-1686.
[8] TERAMOTO K, OHSHIO Y, FUJITA T, et al. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy[J]. J Cancer Res Clin Oncol, 2013, 139(5): 861-870.
[9] BRAUMüLLER H, WIEDER T, BRENNER E, et al. T-helper-1-cell cytokines drive cancer into senescence[J]. Nature, 2013, 494(7437): 361-365.
[10] DUAN M C, ZHONG X N, LIU G N, et al. The Treg/Th17 paradigm in lung cancer[J]. J Immunol Res, 2014, 2014: 730380.
[11] CHANG S H, MIRABOLFATHINEJAD S G, KATTA H,
et al. T helper 17 cells play a critical pathogenic role in lung cancer[J]. Proc Natl Acad Sci U S A, 2014, 111(15): 5664-5669.
[12] 顾磊, 蒋春晖, 孙隆慈, 等. 1,25(OH)_2D_3体外抑制小鼠Th17细胞分化的作用研究[J]. 肝胆胰外科杂志, 2016, 28(3): 213-216.
[13] JIA L, WU C. The biology and functions of Th22 cells[J]. Adv Exp Med Biol, 2014, 841: 209-230.
[14] WOLK K, WITTE E, WITTE K, et al. Biology of interleukin-22[J]. Semin Immunopathol, 2010, 32(1): 17-31.
[15] CHENG F, GUO Z, XU H, et al. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythemato-sus[J]. Ann Rheum Dis, 2009, 68(4): 604-606.
[16] ZENEWICZ L A, YANCOPOULOS G D, VALENZUELA D M, et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation[J]. Immunity, 2007, 27(4): 647-659.
[17] RADAEVA S, SUN R, PAN H N, et al. Interleukin 22(IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 ac-tivation[J]. Hepatology, 2004, 39(5): 1332-1342.
[18] ZHANG Y, COBLEIGH M A, LIAN J Q, et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus[J]. Gastroenterology, 2011, 141(5): 1897-1906.
[19] OGATA H, KOBAYASHI T, CHINEN T, et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis[J]. Gastroenterology, 2006, 131(1): 179-193.
[20] PARK O, WANG H, WENG H, et al. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression[J]. Hepatology, 2011, 54(1): 252-261.
[21] JIANG R, TAN Z, DENG L, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3[J]. Hepatology, 2011, 54(3): 900-909.
[22] 马诗家, 郭晓云, 陶霖, 等. Th22细胞和IL-22在肝癌外周血的表达及与肿瘤标记物的相关性研究[J]. 中国临床新医学, 2014, 7(4): 277-279.